Viridian Therapeutics, Inc. · NASDAQ:VRDN

Viridian Therapeutics — Technical Presentation (November 2026)

21 slides from Viridian Therapeutics's technical presentation, Nov 9, 2026

  1. Slide 1: VRDN-008 Phase 1 Data Disclosure

    VRDN-008 Phase 1 Data Disclosure November 9, 2026

  2. Slide 2: Disclaimers

    Disclaimers Disclosures The information contained in this presentation has been prepared by Viridian Therapeutics, Inc. (the “Company,” “we,” “us” or “our”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation is provided a

  3. Slide 3: Agenda

    Agenda Steve Mahoney CEO Opening Remarks President & Chief Executive Officer Radhika Tripuraneni, MD VRDN-008 Phase 1 Clinical Data Chief Medical Officer Shan Wu, PhD VRDN-008 Opportunity Chief Business Officer Steve Mahoney Closing Remarks President & Chief Executive Officer Steve Mahoney, Presiden

  4. Slide 4: CEO Opening Remarks

    CEO Opening Remarks Steve Mahoney, Chief Executive Officer 4 4

  5. Slide 5: Subcutaneous VRDN-008 HV data demonstrates a potential best-in-class profile among FcRn-targeted therapies

    Subcutaneous VRDN-008 HV data demonstrates a potential best- in-class profile among FcRn-targeted therapies Longest reported half-life of FcRn inhibitors, with deep and sustained IgG reduction • Confirmed half-life of 15-18 days, up to 6x longer than first generation Fc fragments • Sustained IgG red

  6. Slide 6: VRDN-008 data exceeded goals for target product profile

    VRDN-008 data exceeded goals for target product profile Molecule Design Goal: Establish optimized PK profile which Goal: Demonstrate deep and sustained outperforms half-life of first-gen Fc fragments reduction of IgG EXCEEDED EXCEEDED Fc fragment Albumin Demonstrated half life of ~15-18 days, Deep a

  7. Slide 7: VRDN-008 Phase 1 Clinical Data

    VRDN-008 Phase 1 Clinical Data Radhika Tripuraneni, Chief Medical Officer 7 7

  8. Slide 8: VRDN-008 demonstrated sustained IgG reduction through 8 weeks after dosing in healthy volunteers

    VRDN-008 demonstrated sustained IgG reduction through 8 weeks after dosing in healthy volunteers, with 74% reduction at peak VRDN-008 Concentration (PK) VRDN-008 IgG Reduction (PD) Wk 0 Wk 4 Wk 0 Wk 4 1000 (% reduction from baseline) VRDN-008 Concentration 0 IgG reduction 100 -25 (μg/mL) 8 Weeks 8 W

  9. Slide 9: VRDN-008 demonstrated a safety profile that spared albumin and LDL

    VRDN-008 demonstrated a safety profile that spared albumin and LDL and was generally well tolerated VRDN-008 Albumin Levels VRDN-008 LDL Levels Wk 0 Wk 4 Wk 0 Wk 4 200 6 LDL Cholesterol 150 Albumin Normal serum (mg/dL) 4 (g/dL) albumin range1 100 2 50 0 0 0 2 4 6 8 10 12 0 2 4 6 8 10 12 Time (Week)

  10. Slide 10: VRDN-008 IgG modeling reinforces the potential for transformative Q8W subcutaneous dosing

    VRDN-008 IgG modeling reinforces the potential for transformative Q8W subcutaneous dosing Modeled Subcutaneous VRDN-008 IgG Reduction 0 • Modeling results -20 Modeled 3,000 mg SC VRDN-008 Q4W dosing demonstrate sustained IgG Modeled 3,000 mg SC VRDN-008 Q8W dosing after week 4 reductions with Q8W (%

  11. Slide 11: Viridian plans to initiate a subcutaneous VRDN-008 registrational trial in MG in mid-2027

    Viridian plans to initiate a subcutaneous VRDN-008 registrational trial in myasthenia gravis (MG) in mid-2027 Planned VRDN-008 Registrational Trial Design in MG ARM A Dose SC Q8W Every 8 weeks with loading dose Treatment Follow-up at week 4 STUDY RANDOMIZATION ARM B Dose SC Q4W Treatment Follow-up P

  12. Slide 12: VRDN-008 Opportunity

    VRDN-008 Opportunity Shan Wu, Chief Business Officer 12 12

  13. Slide 13: Subcutaneous VRDN-008: potential best-in-class FcRn inhibitor

    Subcutaneous VRDN-008: potential best-in-class FcRn inhibitor  Half-life extended bifunctional FcRn inhibitor  Demonstrated deep and sustained IgG reduction  Potential for best-in-class Q8W dosing VRDN-008  Anticipated simple, subcutaneous, at-home self-administration  Planned rapid development

  14. Slide 14: Current FcRn-targeted therapeutic options do not adequately address patient unmet needs

    Current FcRn-targeted therapeutic options do not adequately address patient unmet needs No single FcRn therapy today addresses the full spectrum of patient needs Potential best-in-class profile ARGX-213 IMVT-1402 Subcutaneous VRDN-008* Half-Life1 3 – 5 days 3 – 5 days < 7 days 1.2 days Undisclosed U

  15. Slide 15: Viridian is developing subcutaneous VRDN-008 using enFuse, a commercially validated device

    Viridian is developing subcutaneous VRDN-008 using enFuse, a commercially validated device Enable enFuse® Large volume autoinjectors The next generation of drug delivery Potential limitations  Expected Q8W subcutaneous • Expected once weekly use delivery • Large form factor  Hands-free self-admini

  16. Slide 16: Subcutaneous VRDN-008 Q8W dosing has the potential to be best-in-class

    Subcutaneous VRDN-008 Q8W dosing has the potential to be best-in-class ILLUSTRATIVE DOSING in MG (Weeks) EST. DOSES REGIMEN / ROA 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 PER YEAR VRDN-

  17. Slide 17: Potential for subcutaneous VRDN-008 in MG and a broad range of autoantibody-mediated autoimmune diseases

    Potential for subcutaneous VRDN-008 in MG and a broad range of autoantibody-mediated autoimmune diseases $50bn1 potential addressable market for VRDN-008 across multiple autoimmune diseases Direct-to-registrational development path FcRn Sales in MG1 MG 1.6x $12bn  Large MG market, with 40% LTM grow

  18. Slide 18: Closing Remarks

    Closing Remarks Steve Mahoney, Chief Executive Officer 18 18

  19. Slide 19: Subcutaneous VRDN-008 unlocks a new franchise for Viridian in autoantibody-mediated autoimmune diseases

    Subcutaneous VRDN-008 unlocks a new franchise for Viridian in a broad set of autoantibody-mediated autoimmune diseases Anticipated PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Approved Milestones Lumvoa Approved in the U.S. Anti-IGF-1R; Intravenous Elegrobart BLA submission Q1 Anti-IGF-1R; Subcutaneous 2027

  20. Slide 20: Building on Viridian's foundation in TED, Viridian aspires to lead across autoimmune diseases

    Building on Viridian’s foundation in TED, Viridian aspires to lead across autoimmune diseases • Plan to develop VRDN-008 in multiple autoantibody- VRDN-008 data mediated autoimmune demonstrates deep and diseases sustained IgG reduction, • Continued pipeline growth supporting potential best-in- thro

  21. Slide 21: Q&A

    24 Q&A SK VIRIDIAN

Viridian Therapeutics — Technical Presentation (November 2026) on 6ix